darovasertib
3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)-2-pyridinyl]-6-[3-(trifluoromethyl)-2-pyridinyl]pyrazine-2-carboxamide
Molecular Identity
darovasertib
3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)-2-pyridinyl]-6-[3-(trifluoromethyl)-2-pyridinyl]pyrazine-2-carboxamide
PubChem CID: 118873253
Darovasertib is an orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, darovasertib inds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells.
2D Structure
Properties
C22H23F3N8O
Molecular Formula
472.50
Molecular Weight
g/mol
472.1947
Exact Mass
Da
1.9
XLogP
Drug-like (Lipinski: < 5)
136
TPSA
Good oral absorption (< 140 A²)
3
H-Bond Donors
11
H-Bond Acceptors
702
Complexity
SMILES
Canonical SMILES
SMILES: Synonyms(20)
darovasertib1874276-76-2LXS196LXS-196NVP-LXS196NVP-LXS-196Darovasertib [USAN]E0YF0M8O09DAROVASERTIB [INN]UNII-E0YF0M8O09DAROVASERTIB [WHO-DD]Darovasertib (USAN)Example 9 [WO2016020864A1]Example 9 (WO2016020864A1)RefChem:130968
Data from PubChem (NCBI)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug Network
Trials and conditions connected to darovasertib
Loading drug network...